« Back
CAR-T Cell-Based Immunotherapy Clinical Applications and Challenges
Poster Title: CAR-T Cell-Based Immunotherapy Clinical Applications and Challenges
Submitted on 30 Jun 2021
Author(s): Creative Biolabs
This poster was presented at
Poster Views: 82
View poster »

Poster Information
Abstract: Immunotherapy has become a revolution in the area of cancer treatment. Compared to the traditional methods, such as invasive surgeries, radiation and chemotherapy, immunotherapy is more specific and less toxic to patients. Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies, with up to 95% response rates and durable complete remission. A CAR mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region and an internal signaling domain such as CD3ζ. The main advantage of CAR-T cell is that it bypasses MHC restriction, which allows for direct activation of effector cells for the treatment of various types of tumors.Summary: Creative Biolabs is a world-renowned service provider for immunotherapy. We have one of the world’s largest collection of CAR products of different generations targeting various biomarkers, and we continue to innovate the next generation CAR technologies to achieve even greater results. Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons